Multimodal Educative Data Feedback for Deprescribing BZD and Related Drugs in Outpatients: a Cluster RCT

NCT05859555 | Completed

• 1 other identifier: BZD001
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Benzodiazepine (BZD) and related drugs are sedative anxiolytics and hypnotics that should be avoided especially in people aged 65 years and older, given the high risk of falling, fracture, dependence, respiratory depression and cognitive disorders. Despite these contraindications, their consumption continues to increase in Switzerland. Although it can be assumed that deprescribing a drug has a direct benefit, it is nevertheless necessary to determine how to implement this process effectively and safely. To change healthcare professionals' prescribing behaviours for BZD, the most common deprescribing interventions include identification of appropriate patients, education and training of GPs and patients, and gradual and appropriate reduction of the dose of BZD. Thus, the DELTA CARE NETWORK and the DELTA VAUD CARE NETWORK have set themselves the task of evaluating the effectiveness of a multimodal deprescribing intervention for Delta primary care physicians and their patients aged 65 and over, in the cantons of Geneva and Vaud. The goal is to reduce the total BZD prescription rate among this population. This quality development project is fully in line with the Quality Federal Commission's objectives of efficiency, safety, patient-centred and in the interests of the patient.

Conditions

Deprescription; Benzodiazepine (BZD) and Related Drugs

Keywords

Benzodiazepine (BZD) and related drugs; Deprescribing; Safety; Older patients

Outcome Measures

Primary Outcomes (1)

• Rate Benzodiazepine (BZD) and related drugs prescribed by primary care physicians

  Reduce the total BZD prescribing frequency by 20% 9 months after the interventioncompared to the control group (DDD/1000 patients over 9 months). The drug measure will be the DDD daily dose defined by the World Health Organization Collaborating Centre for Drug Statistics Methodology (or number of tablets or number of packages).

  9 months

Secondary Outcomes (1)

• Rate of patients aged 65 years who took long-term BZD

  18 months

Study Arms (2)

Intervention: Thematic quality circles - Deprescription

OTHER

Other: Thematic quality circles - Deprescription

No intervention

NO INTERVENTION

Interventions

Thematic quality circles - Deprescription OTHER

Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)

Intervention: Thematic quality circles - Deprescription

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Physician who attended a quality cercle in the cantons of Geneva and Vaud
• Prescribed at least one prescription of Benzodiazepines during the year of analysis to patient aged 65 years and older

Sponsors & Collaborators

• Réseau de soins Delta: lead

Study Sites (1)

Réseau de soins Delta SA

Geneva, Petit Lancy, Switzerland

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Project Manager

Model Details: Cluster randomised controlled trial

Study Record Dates

• First Submitted: March 19, 2023
• First Posted: May 16, 2023
• Study Start: December 5, 2022
• Primary Completion: May 21, 2024
• Study Completion: June 21, 2024
• Last Updated: November 29, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)